Literature DB >> 18795706

Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.

Veysel Tahan1, Billur Canbakan, Huriye Balci, Faysal Dane, Hakan Akin, Guray Can, Ibrahim Hatemi, Vakur Olgac, Abdullah Sonsuz, Gulsen Ozbay, Ibrahim Yurdakul, Hakan Senturk.   

Abstract

BACKGROUND/AIMS: Hepatocyte apoptosis is an important and invasive predictor of liver injury and fibrosis in non-alcoholic fatty liver disease (NAFLD). Increased gamma-glutamyltranspeptidase (GGT) level is frequently observed in NAFLD. Hepatocyte growth factor (HGF) stimulates fibrogenesis and is correlated with GGT. The study aimed to determine whether GGT can distinguish NAFLD patients at high risk.
METHODOLOGY: Fifty biopsy-proven NAFLD patients (M/F: 24/26) were divided as the normal GGT group (n = 25) and the high GGT group (n = 25) (each patients' GGT > two fold of upper-limit of normal). Liver histology was graded according to Brunt et al. TNF-sRp55, caspase-3 and 8, NFkappaB and Bcl-2 were measured by immunohistochemical methods. For statistical analysis, Student's t test, chi-square test, multivariate regression analysis and the area under receiver operating characteristic (ROC) curve were used.
RESULTS: The high GGT group had significantly higher NFkappaB, caspase-3 and 8, and Bcl-2 levels (54.52 +/- 26.02, p = 0.002; 55.95 +/- 27.18, p = 0.002; 47.85 +/- 28.04, p = 0.001; 11.19 +/- 12.33, p = 0.016, respectively). Serum TNF-sRp55 levels of both groups were similar (2922.93 +/- 307.26, and 2885 +/- 194.47; p = 0.78). Differences in reference to histological steatosis grade and inflammation were not significant. However, fibrosis stage was higher in the high GGT group (p = 0.048).
CONCLUSION: Multinominal logistic regression analysis showed that increased GGT level was a risk factor for advanced fibrosis in NAFLD (OR: 1.0, CI: 0.98-1.01; p =0.032). Using serum GGT levels the area under the ROC curve for the prediction of advanced fibrosis was 0.74 (95% CI: 0.54-0.94). The serum GGT cut-off value for the prediction of advanced fibrosis was 96.5 U/L; with 83% sensitivity and 69% specificity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795706

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  32 in total

1.  Central body fat distribution associates with unfavorable renal hemodynamics independent of body mass index.

Authors:  Arjan J Kwakernaak; Dorien M Zelle; Stephan J L Bakker; Gerjan Navis
Journal:  J Am Soc Nephrol       Date:  2013-04-11       Impact factor: 10.121

2.  Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Francesco Scopacasa; Annamaria Colao; Domenico Capone; Marianna Tarantino; Ernesto Grimaldi; Silvia Savastano
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

3.  Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.

Authors:  Anil Arora; Praveen Sharma
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

Review 4.  Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease.

Authors:  Pierluigi Marzuillo; Anna Grandone; Laura Perrone; Emanuele Miraglia Del Giudice
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

5.  Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.

Authors:  Sun-pyo Hong; Tae Soo Noh; Seung-Hwan Moon; Young Seok Cho; Eun Jeong Lee; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Dig Dis Sci       Date:  2013-12-11       Impact factor: 3.199

6.  Alcohol, metabolic risk and elevated serum gamma-glutamyl transferase (GGT) in Indigenous Australians.

Authors:  Matthew T Haren; Ming Li; John Petkov; Robyn A McDermott
Journal:  BMC Public Health       Date:  2010-08-03       Impact factor: 3.295

Review 7.  From fatty liver to fibrosis: a tale of "second hit".

Authors:  Metin Basaranoglu; Gökcen Basaranoglu; Hakan Sentürk
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

Review 8.  Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.

Authors:  Neven Baršić; Ivan Lerotić; Lea Smirčić-Duvnjak; Vedran Tomašić; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

9.  Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?

Authors:  Ahilan Arulanandan; Rohit Loomba
Journal:  Curr Hepatol Rep       Date:  2015-04-22

10.  Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist.

Authors:  Seung-Hee Lee; Vimal Veeriah; Fred Levine
Journal:  Cell Death Dis       Date:  2021-06-11       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.